最近一周医渡科技已累计进行4次回购，合计回购约275.1万股，累计回购金额超过1600万港元。若将时 间线拉长至9月26日起，该股已完成6次回购，累计回购金额近2000万港元。 市场资金动向方面，据Wind最新数据，南向资金10月15日净买入医渡科技357.62万股，占当日成交量比 例为32.24%。从增减持金额来看，以增减持数量和成交均价为基准进行测算，南向资金当日净买入医 渡科技2113.53万港元，连续4日净买入，累计净买入7807万港元。 智通财经APP获悉，根据医渡科技(02158)最新公告，公司于10月20日再次回购股份，单日斥资37万港元 购回6.62万股。 ...

医渡科技(02158)发布公告，于2025年10月20日，该公司斥资37.23万港元回购6.62万股股份，每股回购 价格为5.59-5.65港元。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2025年10月20日，该公司斥资37.23万港元回购6.62万股 股份，每股回购价格为5.59-5.65港元。 ...

格隆汇10月20日丨医渡科技(02158.HK)公告，10月20日耗资37.2万港元回购6.6万股，每股回购价5.59- 5.65港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Summary of Key Points Core Viewpoint - On October 17, 42 Hong Kong-listed companies conducted share buybacks, totaling 46.36 million shares and an aggregate amount of HKD 621 million [1][2]. Company-Specific Summaries - **Xiaomi Group-W**: - Repurchased 10.70 million shares for HKD 494 million, with a highest price of HKD 46.760 and a lowest price of HKD 45.900. The total buyback amount for the year reached HKD 1.537 billion [1][2]. - **Sihuan Pharmaceutical**: - Repurchased 15 million shares for HKD 21.76 million, with a highest price of HKD 1.470 and a lowest price of HKD 1.430. The total buyback amount for the year reached HKD 143.32 million [1][2]. - **Mengniu Dairy**: - Repurchased 1.20 million shares for HKD 16.97 million, with a highest price of HKD 14.250 and a lowest price of HKD 14.070. The total buyback amount for the year reached HKD 433.54 million [1][2]. - **AAC Technologies**: - Repurchased 300,000 shares for HKD 11.60 million, with a highest price of HKD 38.800 and a lowest price of HKD 38.480. The total buyback amount for the year reached HKD 84.64 million [1][2]. - **Vitasoy International**: - Repurchased 1.02 million shares for HKD 8.20 million, with a highest price of HKD 8.040 and a lowest price of HKD 8.020. The total buyback amount for the year reached HKD 27.54 million [1][2]. Overall Market Activity - The highest buyback amount on October 17 was from Xiaomi Group-W at HKD 494 million, followed by Sihuan Pharmaceutical at HKD 21.76 million. Other notable companies included Mengniu Dairy and AAC Technologies [1][2]. - In terms of share quantity, Sihuan Pharmaceutical led with 15 million shares repurchased, followed by Xiaomi Group-W with 10.70 million shares and Anton Oilfield Services with 4.49 million shares [1][2].

Core Viewpoint - Multiple companies in China conducted share buybacks on October 17, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1][2] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 10.70 million shares for a total of 494 million yuan, with a year-to-date total of 27.30 million shares, representing 0.110% of its total share capital [2] - Four Seasons Pharmaceutical (00460) repurchased 15 million shares for 21.76 million yuan, with a year-to-date total of 59.60 million shares, representing 0.647% of its total share capital [2] - Mengniu Dairy (02319) repurchased 1.20 million shares for 16.97 million yuan, with a year-to-date total of 18.52 million shares, representing 0.473% of its total share capital [2] Group 2: Other Notable Buybacks - VITASOY International (00345) repurchased 1.02 million shares for 8.20 million yuan, with a year-to-date total of 566.60 million shares, representing 0.540% of its total share capital [2] - Zhongtong Express-W (02057) repurchased 445,000 shares for 8.41 million yuan, with a year-to-date total of 5.07 million shares, representing 0.630% of its total share capital [2] - Huazhong Media (00685) repurchased 500,000 shares for 50,000 yuan, with a year-to-date total of 225.60 million shares, representing 0.139% of its total share capital [2]

消息面上，近日全球首款针对增殖期浅表性婴儿血管瘤的局部外用治疗制剂——马来酸噻吗洛尔凝胶获 批上市，医渡科技提供关键的市场调研和项目调研分析服务，为药物的研发与上市路径提供了重要支 持。 本周以来，医渡科技累计进行3次回购，合计回购约268.5万股，累计回购金额超过1560万港元。9月26 日以来该股累计进行5次回购，合计回购约337.3万股，累计回购金额近2000万港元。 另据最新数据，南向资金10月14日净买入医渡科技3472.73万港元，净买入额创2025年9月1日以来新 高，并且已连续3日净买入，累计净买入5779万港元。 医渡科技(02158)最新公告显示，10月17日公司耗资101.3万港元回购18.1万股。 ...

Core Viewpoint - 医渡科技 announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company plans to repurchase 181,200 shares at a total cost of HKD 1.0131 million [1] - The buyback price per share ranges from HKD 5.56 to HKD 5.65 [1] - The buyback is scheduled for October 17, 2025, reflecting a strategic move to enhance shareholder value [1]

智通财经APP讯，医渡科技(02158)发布公告，于2025年10月17日，该公司斥资101.31万港元回购18.12万 股股份，每股回购价格为5.56-5.65港元。 ...